Thursday, March 07, 2024 10:48:15 AM
Recent NRSN News
- NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission • PR Newswire (US) • 10/28/2024 12:30:00 PM
- New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients • PR Newswire (US) • 10/24/2024 12:30:00 PM
- NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates • PR Newswire (US) • 10/15/2024 01:15:00 PM
- NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada • PR Newswire (US) • 10/09/2024 01:00:00 PM
- NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting • PR Newswire (US) • 10/07/2024 01:00:00 PM
- NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's • PR Newswire (US) • 09/24/2024 01:05:00 PM
- NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule • PR Newswire (US) • 09/24/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2024 09:00:06 PM
- NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification • PR Newswire (US) • 08/30/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/28/2024 11:05:11 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/26/2024 12:00:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2024 08:06:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 08:05:36 PM
- NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price • PR Newswire (US) • 08/07/2024 06:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/07/2024 01:00:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2024 01:24:12 PM
- NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial • PR Newswire (US) • 08/01/2024 01:15:00 PM
- NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression • PR Newswire (US) • 07/09/2024 01:27:00 PM
- NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug • PR Newswire (US) • 07/01/2024 12:00:00 PM
- NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results • PR Newswire (US) • 06/24/2024 01:00:00 PM
- NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal • PR Newswire (US) • 06/21/2024 08:30:00 PM
- NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit • PR Newswire (US) • 05/20/2024 01:00:00 PM
- NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning • PR Newswire (US) • 05/14/2024 01:05:00 PM
- NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients • PR Newswire (US) • 05/07/2024 12:45:00 PM
- NeuroSense Announces First Quarter 2024 Business Update • PR Newswire (US) • 05/02/2024 01:19:00 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM